• Login
    View Item 
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER(+) breast cancer

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    36376284.pdf
    Size:
    526.7Kb
    Format:
    PDF
    Description:
    Identified with Open Access button
    Download
    Authors
    Palafox, M.
    Monserrat, L.
    Bellet, M.
    Villacampa, G.
    Gonzalez-Perez, A.
    Oliveira, M.
    Brasó-Maristany, F.
    Ibrahimi, N.
    Kannan, S.
    Mina, L.
    Herrera-Abreu, M. T.
    Òdena, A.
    Sánchez-Guixé, M.
    Capelán, M.
    Azaro, A.
    Bruna, A.
    Rodríguez, O.
    Guzmán, M.
    Grueso, J.
    Viaplana, C.
    Hernández, J.
    Su, F.
    Lin, K.
    Clarke, Robert B
    Caldas, C.
    Arribas, J.
    Michiels, S.
    García-Sanz, A.
    Turner, N. C.
    Prat, A.
    Nuciforo, P.
    Dienstmann, R.
    Verma, C. S.
    Lopez-Bigas, N.
    Scaltriti, M.
    Arnedos, M.
    Saura, C.
    Serra, V.
    Show allShow less
    Affiliation
    Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
    Issue Date
    2022
    
    Metadata
    Show full item record
    Citation
    Palafox M, Monserrat L, Bellet M, Villacampa G, Gonzalez-Perez A, Oliveira M, et al. Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER(+) breast cancer. Nature communications. 2022 Nov 14;13(1):6928. PubMed PMID: 36376284. Epub 2022/11/15. eng.
    Journal
    Nature Communications
    URI
    http://hdl.handle.net/10541/625771
    DOI
    10.1038/s41467-022-34580-3
    PubMed ID
    36376284
    Additional Links
    https://dx.doi.org/10.1038/s41467-022-34580-3
    Type
    Erratum
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1038/s41467-022-34580-3
    Scopus Count
    Collections
    All Paterson Institute for Cancer Research

    entitlement

    Related articles

    • High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER(+) breast cancer.
    • Authors: Palafox M, Monserrat L, Bellet M, Villacampa G, Gonzalez-Perez A, Oliveira M, Brasó-Maristany F, Ibrahimi N, Kannan S, Mina L, Herrera-Abreu MT, Òdena A, Sánchez-Guixé M, Capelán M, Azaro A, Bruna A, Rodríguez O, Guzmán M, Grueso J, Viaplana C, Hernández J, Su F, Lin K, Clarke RB, Caldas C, Arribas J, Michiels S, García-Sanz A, Turner NC, Prat A, Nuciforo P, Dienstmann R, Verma CS, Lopez-Bigas N, Scaltriti M, Arnedos M, Saura C, Serra V
    • Issue date: 2022 Sep 7
    • Comparative analysis of Rb1, P16 and ER as diagnostic, prognostic and potential targets for therapeutic agents in ovarian epithelial tumors: an immunohistochemical study of 130 ovarian carcinomas.
    • Authors: Ferguson DC, Long DJ, Smith MC, Craig-Owens LD, Means J, Fadare O, Desouki MM
    • Issue date: 2015 Jun 5
    • Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
    • Authors: Xi J, Ma CX
    • Issue date: 2020 May 16
    • LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer.
    • Authors: Jin X, Ge LP, Li DQ, Shao ZM, Di GH, Xu XE, Jiang YZ
    • Issue date: 2020 May 11
    • Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    • Authors: Ogata R, Kishino E, Saitoh W, Koike Y, Kurebayashi J
    • Issue date: 2021 Jan
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.